Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| EWTX | 8-K | bullish | 7/10 | Edgewise Therapeutics completed the sale of its sevasemten muscular dystrophy program to Servier for $1.55 billion in up | Jul 13, 2026 |
| MTNB | 8-K | bearish | 7/10 | Matinas BioPharma entered into a definitive business combination agreement with GH Power, a clean-energy company, in a r | Jul 13, 2026 |
| ANRO | 8-K | bullish | 6/10 | Alto Neuroscience disclosed a preliminary cash balance of ~$244.2M as of June 30, 2026 (down from $264.2M at Q1 end) and | Jul 13, 2026 |
| ANIP | PRESS-RELEASE | bullish | 6/10 | ANI Pharmaceuticals reported positive topline Phase 4 data for ILUVIEN in chronic non-infectious uveitis affecting the p | Jul 13, 2026 |
| RDY | 6-K | neutral | 2/10 | Dr. Reddy's Laboratories filed a Form 6-K to announce the date of its Q1 FY27 earnings release and earnings call on July | Jul 13, 2026 |
| GSK | 6-K | bullish | 6/10 | GSK announced positive interim results from the registrational phase II AZUR-1 trial of Jemperli (dostarlimab) in dMMR/M | Jul 13, 2026 |
| AGEN | 8-K | bearish | 6/10 | Agenus entered into a securities purchase agreement for a ~$85M PIPE financing led by Commodore Capital, issuing shares | Jul 13, 2026 |
| BIIB | ANALYST-UPGRADE | bullish | 3/10 | Truist Securities double-upgraded Biogen (BIIB) from Hold to Buy on July 13, raising the price target to $235 from $190, | Jul 13, 2026 |
| AMPH | 8-K | neutral | 2/10 | Amphastar Pharmaceuticals appointed Anthony Pierce as a new independent Class III director, expanding the board from 10 | Jul 13, 2026 |
| AVCRF | 6-K | neutral | 2/10 | Analysis based on filing metadata only, document content was unavailable. Avricore Health Inc. filed a Form 6-K with the | Jul 13, 2026 |
| CBIO | EFFECT | neutral | 3/10 | Analysis based on filing metadata only, document content was unavailable. Crescent BioPharma's registration statement ha | Jul 13, 2026 |
| ONMD | EFFECT | neutral | 3/10 | Analysis based on filing metadata only, document content was unavailable. OneMedNet Corp (ONMD) filed an EFFECT notice i | Jul 13, 2026 |
| INO | EFFECT | bearish | 6/10 | Inovio Pharmaceuticals' universal shelf registration (S-3) filed July 2, 2026 has become effective, allowing the company | Jul 13, 2026 |
| CRVO | EFFECT | bearish | 4/10 | CervoMed Inc.'s shelf registration (S-3) has become effective via an EFFECT notice, enabling selling stockholders to res | Jul 13, 2026 |
| EVAX | 6-K | neutral | 3/10 | Evaxion announced new preclinical data for its CMV vaccine program EVX-V1, presented at an industry conference. The data | Jul 13, 2026 |
| ALMR | PRESS-RELEASE | neutral | 4/10 | Alamar Biosciences announced a partnership with leading research universities to profile ~21,000 plasma samples from 10, | Jul 13, 2026 |
| EVAX | PRESS-RELEASE | neutral | 3/10 | Evaxion presented new preclinical data at the International Herpesvirus Workshop 2026 for its CMV vaccine program EVX-V1 | Jul 12, 2026 |
| NVO | COURT-RULING | neutral | 2/10 | The court granted a fourth joint stipulation to stay discovery in Novo Nordisk's case against Aesthetic Center of Plasti | Jul 11, 2026 |
| APGE | CLUSTER | neutral | 2/10 | CEO Michael Thomas Henderson sold $2.67M and CMO Carl Dambkowski sold $730K of APGE shares in a small cluster. Combined | Jul 10, 2026 |
| EVMN | CLUSTER | neutral | 3/10 | Two Evommune insiders (Director Arthur S. Kirsch and CFO Kyle Carver) made open-market stock purchases totaling $146K ov | Jul 10, 2026 |
| PALI | CLUSTER | neutral | 2/10 | A small insider cluster at Palisade Bio (PALI) shows mixed activity: Director Baltera purchased ~$191K worth of shares o | Jul 10, 2026 |
| CMND | 6-K | neutral | 3/10 | Clearmind Medicine submitted a formal response to the HHS RFI on addiction treatment innovations as part of the Great Am | Jul 10, 2026 |
| CRNX | 8-K | bullish | 6/10 | Crinetics Pharmaceuticals filed this 8-K to disclose non-compete agreements with its CEO, CFO, CSO, and CCO in connectio | Jul 10, 2026 |
| AZN | COURT-RULING | bullish | 7/10 | The Federal Circuit affirmed the district court's grant of JMOL of invalidity for lack of enablement of Wyeth's asserted | Jul 10, 2026 |
| TRAW | 8-K | bearish | 6/10 | Traws Pharma filed an 8-K to establish an at-the-market (ATM) equity offering program, allowing it to sell up to $5,575, | Jul 10, 2026 |
| CRNX | DEFA14A | bullish | 7/10 | Crinetics Pharmaceuticals filed this DEFA14A as soliciting material in connection with its pending merger with Vertex Ph | Jul 10, 2026 |
| CYCN | 425 | mixed | 6/10 | Cyclerion Therapeutics (CYCN) filed a Korsana Biosciences investor presentation in connection with their proposed revers | Jul 10, 2026 |
| CALC | 3 | neutral | 2/10 | Alafi Capital Co LLC filed a Form 3 initial statement of beneficial ownership with the SEC, disclosing ownership of 5,11 | Jul 10, 2026 |
| MRNA | 3 | neutral | 2/10 | Michael McDonnell filed a Form 3 initial statement of beneficial ownership with Moderna, indicating he has become an off | Jul 10, 2026 |
| NAGE | 424B5 | bearish | 6/10 | Niagen Bioscience filed a 424B5 prospectus supplement for an at-the-market offering of up to $50 million in common stock | Jul 10, 2026 |